+

WO2013016598A3 - Methods for reducing reperfusion injury using a hemoglobin-based carbon monoxide carrier - Google Patents

Methods for reducing reperfusion injury using a hemoglobin-based carbon monoxide carrier Download PDF

Info

Publication number
WO2013016598A3
WO2013016598A3 PCT/US2012/048450 US2012048450W WO2013016598A3 WO 2013016598 A3 WO2013016598 A3 WO 2013016598A3 US 2012048450 W US2012048450 W US 2012048450W WO 2013016598 A3 WO2013016598 A3 WO 2013016598A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbon monoxide
hemoglobin
methods
based carbon
reperfusion injury
Prior art date
Application number
PCT/US2012/048450
Other languages
French (fr)
Other versions
WO2013016598A2 (en
Inventor
Mark Young
Kim D. Vandegriff
Original Assignee
Sangart, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangart, Inc. filed Critical Sangart, Inc.
Publication of WO2013016598A2 publication Critical patent/WO2013016598A2/en
Publication of WO2013016598A3 publication Critical patent/WO2013016598A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates generally to methods for reducing reperfusion injury. Specifically, the present invention is directed to administering a hemoglobin-based carbon monoxide carrier to a subject, prior to or following surgery, to reduce injury resulting from reperfusion by delivering both carbon monoxide and oxygen to ischemic tissue.
PCT/US2012/048450 2011-07-27 2012-07-27 Methods for reducing reperfusion injury using a hemoglobin-based carbon monoxide carrier WO2013016598A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512335P 2011-07-27 2011-07-27
US61/512,335 2011-07-27

Publications (2)

Publication Number Publication Date
WO2013016598A2 WO2013016598A2 (en) 2013-01-31
WO2013016598A3 true WO2013016598A3 (en) 2013-03-21

Family

ID=47601767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/048450 WO2013016598A2 (en) 2011-07-27 2012-07-27 Methods for reducing reperfusion injury using a hemoglobin-based carbon monoxide carrier

Country Status (1)

Country Link
WO (1) WO2013016598A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018138360A1 (en) 2017-01-28 2018-08-02 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Oxygen carrying blood substitutes and their use as delivery vehicles
US11504417B2 (en) 2017-07-18 2022-11-22 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making
CN114377155B (en) * 2022-01-14 2023-11-10 吴诗熳 Contrast agent, preparation method of contrast agent and application of contrast agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888249A (en) * 1973-11-02 1975-06-10 David L Spencer Arterial infusion catheter
US20060234915A1 (en) * 2005-03-07 2006-10-19 Sangart, Inc. Compositions and methods for delivering carbon monoxide (CO) and nitric oxide (NO) to tissue using heme proteins as carriers
US7625862B2 (en) * 2002-01-11 2009-12-01 Sangart, Inc. Method for making a high oxygen affinity modified hemoglobin for oxygen transport
US20120196270A1 (en) * 2011-02-02 2012-08-02 Sangart, Inc. Methods for preserving an organ for transplantation using a hemoglobin-carbon monoxide complex

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888249A (en) * 1973-11-02 1975-06-10 David L Spencer Arterial infusion catheter
US7625862B2 (en) * 2002-01-11 2009-12-01 Sangart, Inc. Method for making a high oxygen affinity modified hemoglobin for oxygen transport
US20060234915A1 (en) * 2005-03-07 2006-10-19 Sangart, Inc. Compositions and methods for delivering carbon monoxide (CO) and nitric oxide (NO) to tissue using heme proteins as carriers
US20090082257A1 (en) * 2005-03-07 2009-03-26 Sangart, Inc. MalPEG-Hb conjugate- containing compositions for delivering carbon monoxide (CO) to cells
US20120196270A1 (en) * 2011-02-02 2012-08-02 Sangart, Inc. Methods for preserving an organ for transplantation using a hemoglobin-carbon monoxide complex

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BURMEISTER M ET AL.: "Effect of prophylactic or therapeutic application of bovine haemoglobin HBOC-200 on ischaemia-reperfusion injury following acute coronary ligature in rats.", BR J ANAESTH, vol. 95, 2005, pages 737 - 745 *
CRETEUR ET AL.: "Potential Uses of Hemoglobin-based Oxygen Carriers in Critical Care Medicine", vol. 25, 2009, pages 311 - 324 *

Also Published As

Publication number Publication date
WO2013016598A2 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
MX2014001180A (en) Nuclear transport modulators and uses thereof.
EP4234545A3 (en) Hydrazide containing nuclear transport modulators and uses thereof
PH12014501702A1 (en) Imidazopyrrolidinone compounds
EA026892B9 (en) TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
TW201144301A (en) Processes for preparing linezolid
MY165568A (en) Sulfur-containing palladium/carbon catalyst, preparation method therefor, and method for preparing p-phenylenediamine antioxidant
GB2517868A (en) Improved travel support structure
WO2013052907A3 (en) Methods and processes for non-invasive assessment of genetic variations
MX359651B (en) Cxcr7 antagonists.
WO2012065102A8 (en) S-t-butyl protected cysteine di-peptide analogs and related compounds
MY189659A (en) Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
NZ598972A (en) Spiro-indoline-piperidine derivatives as selective GPR-40 activators for treating diabetes
NZ606589A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
MX360030B (en) Methods for treating bipolar disorder.
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
TN2011000403A1 (en) Compositions and methods for extended therapy wiht aminopyridines
WO2012168837A3 (en) Method of treating articles with carbon dioxide
WO2012131001A3 (en) Cushion for patient interface
WO2011069159A3 (en) Bis[thiohydrazide amide] compounds for treating leukemia
EP2558150A4 (en) Nasal cannula for carbon dioxide sampling
WO2014145236A3 (en) The use of sdf-1 to mitigate scar formation
WO2013016598A3 (en) Methods for reducing reperfusion injury using a hemoglobin-based carbon monoxide carrier
MX358785B (en) Diaspirin crosslinked pegylated hemoglobin.
GEP20125680B (en) Carbonic and sulphuric acid salts of 3-(2,2,2-trimethylhydra-zinium) ropionate esters and their use for 3-(2,2,2-rimethyl- hydrazinium) propionate dihydrate preparation
WO2011000945A3 (en) Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12817689

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12817689

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载